Home Cart Sign in  
Chemical Structure| 309947-86-2 Chemical Structure| 309947-86-2

Structure of 309947-86-2

Chemical Structure| 309947-86-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 309947-86-2 ]

CAS No. :309947-86-2
Formula : C15H21N5O4
M.W : 335.36
SMILES Code : O=C(OC(C)(C)C)N(C(OC(C)(C)C)=O)C1=C2NC=NC2=NC=N1
MDL No. :MFCD17676144
InChI Key :WNOSWAQZBWMIGM-UHFFFAOYSA-N
Pubchem ID :10497007

Safety of [ 309947-86-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 309947-86-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 24
Num. arom. heavy atoms 9
Fraction Csp3 0.53
Num. rotatable bonds 7
Num. H-bond acceptors 7.0
Num. H-bond donors 1.0
Molar Refractivity 87.77
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

110.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.52
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.35
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.03
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.92
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.98
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.96

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.22
Solubility 0.204 mg/ml ; 0.000609 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-4.31
Solubility 0.0166 mg/ml ; 0.0000494 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.27
Solubility 0.179 mg/ml ; 0.000535 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.68 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.05

Application In Synthesis of [ 309947-86-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 309947-86-2 ]

[ 309947-86-2 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 309947-86-2 ]
  • [ 309947-88-4 ]
  • 2
  • [ 309947-84-0 ]
  • [ 309947-86-2 ]
YieldReaction ConditionsOperation in experiment
79.5% With sodium hydrogencarbonate; In methanol; at 50℃; for 0.5h; Sb2 (500mg, 1.1mmol) was dissolved in methanol (13ml), then added (6.5ml) of saturated NaHCO3 solution, then placed in an oil bath at 50 C for 0.5h, after TLC detection reaction was completed, diluted with plenty of EA water Wash twice, then wash twice with saturated NaCl, dry Na2SO4, concentrate, top column, and quickly pass through the column with (PE/EA=1:1).The white solid product S2 (306.1 mg, 79.5%) was obtained.
With sodium hydrogencarbonate; In methanol; at 50℃; for 2h; Step 2: The above residue was solved in 20 mL methanol, which was followed by adding 20% sodium bicarbonate solution (4 mL), the mixture was stirred at 50 C for 2 hrs, which was then purified by a flash chromatography (PE/EA=6/1) to give white solid as the desired product. NMR (400 MHz, DMSO) delta: 13.70 (s, 1H), 8.79 (s, 1H), 8.64 (s, 1H), 1.37 (s, 18H). LC-MS: m/z 336.4 (M+H)+
  • 3
  • [ 5720-05-8 ]
  • [ 309947-86-2 ]
  • di(tert-butyl) 9-p-tolyl-9H-purin-6-yliminodicarbonate [ No CAS ]
  • 4
  • [ 5467-74-3 ]
  • [ 309947-86-2 ]
  • di(tert-butyl) 9-(4-bromophenyl)-9H-purin-6-yliminodicarbonate [ No CAS ]
  • 6
  • [ 5720-07-0 ]
  • [ 309947-86-2 ]
  • di(tert-butyl) 9-(4-methoxyphenyl)-9H-purin-6-yliminodicarbonate [ No CAS ]
  • 7
  • [ 129423-29-6 ]
  • [ 309947-86-2 ]
  • di(tert-butyl) 9-(3-phenylprop-1-enyl)-9H-purin-6-yliminodicarbonate [ No CAS ]
  • 8
  • 2,4,5-trimethylphenylboronic acid [ No CAS ]
  • [ 309947-86-2 ]
  • di(tert-butyl) 9-(2,4,5-trimethylphenyl)-9H-purin-6-yliminodicarbonate [ No CAS ]
  • 9
  • [ 309947-86-2 ]
  • [ 98-80-6 ]
  • di(tert-butyl) 9-phenyl-9H-purin-6-yliminodicarbonate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper diacetate; triethylamine; In N,N-dimethyl-formamide; at 20℃; for 96h;Molecular sieve; General procedure: To a solution of 3 (100 mg, 0.30 mmol), phenylboronic acid (75 mg, 0.61mmol), andtriethylamine (60 muL), in dry DMF (1.5 mL) was added copper (II) acetate (90 mg, 0.50 mmol)and 5A molecular sieves (300 mg). The resulting mixture was stirred for 4 days at ambienttemperature under air. Volatiles were evaporated and the crude material was re-dissolved in dryMeOH (3.0 mL). To this solution K2CO3 (100mg, 0.72 mmol) was added and the mixture wasstirred for 12 h at ambient temperature. Volatiles were evaporated and the crude was partitioned(CH2Cl2//H2O). The organic layer was separated and dried over Na2SO4. Flash chromatography(70% EtOAc/Hexanes) gave 6a (30 mg, 0.10 mmol, 33%). 1H NMR (CDCl3, 500MHz) delta 8.84 (s,1H), 8.24 (s, 1H), 8.15 (bs, 1H), 7.74 (d, J = 8.0, 2H), 7.62 (t, J = 7.5, 2H), 7.51 (t, J = 7.5, 1H),1.60 (s, 9H); 13C NMR (CDCl3, 125MHz) delta 153. 7, 150.3, 149.7, 141.3, 134.3, 130.0, 128.6,123.5, 82.4, 28.2; HRMS = [M+H] 312.1456; C16H18N5O2 = 312.1460.
  • 10
  • [ 877651-72-4 ]
  • [ 309947-86-2 ]
  • C23H33N5O6 [ No CAS ]
  • 11
  • [ 96-41-3 ]
  • [ 309947-86-2 ]
  • C20H29N5O4 [ No CAS ]
  • 12
  • [ 60410-16-4 ]
  • [ 309947-86-2 ]
  • C22H29N5O6 [ No CAS ]
  • 13
  • [ 163226-45-7 ]
  • [ 309947-86-2 ]
  • (1R,4R,5S)-9-N-[3-(trityloxymethyl)-4,5-O,O-isopropylidene-2-cyclopenten-L-yl]N6,N6-bis-(tert-butoxycarbonyl)adenine [ No CAS ]
  • 14
  • [ 185622-63-3 ]
  • [ 309947-86-2 ]
  • C23H31N5O6 [ No CAS ]
  • 15
  • [ 309947-86-2 ]
  • [ 698999-23-4 ]
  • C25H35N5O6 [ No CAS ]
  • 16
  • [ 303963-93-1 ]
  • [ 309947-86-2 ]
  • [ 952418-11-0 ]
  • 19
  • [ 309947-86-2 ]
  • [ 72877-50-0 ]
  • 20
  • [ 309947-86-2 ]
  • neplanocin A [ No CAS ]
  • 21
  • [ 309947-86-2 ]
  • [ 111005-70-0 ]
  • 22
  • [ 309947-86-2 ]
  • [ 125409-63-4 ]
  • 23
  • [ 309947-86-2 ]
  • [ 158799-95-2 ]
  • 24
  • [ 309947-86-2 ]
  • N9-(4-bromophenyl)adenine [ No CAS ]
  • 25
  • [ 309947-86-2 ]
  • [ 127820-21-7 ]
  • 26
  • (+/-)-t-1-(tert-butyldiphenylsilyloxy)methyl-4-hydroxy-7-oxabicyclo-[3.3.0]oct-2-ene-8-one [ No CAS ]
  • [ 309947-86-2 ]
  • C29H31N5O3Si [ No CAS ]
  • 27
  • [ 1009810-92-7 ]
  • [ 309947-86-2 ]
  • C26H36FN5O6 [ No CAS ]
  • 28
  • [ 309947-86-2 ]
  • [ 5437-45-6 ]
  • [ 1108637-35-9 ]
  • 29
  • [ 1150503-06-2 ]
  • [ 309947-86-2 ]
  • [ 1150502-75-2 ]
  • 30
  • [ 1192851-94-7 ]
  • [ 309947-86-2 ]
  • N-[9-(2,4-bis(benzyloxy)-5-cyclohexylmethoxy-benzyl)-9H-purin-6-yl]-N-(2,2-dimethyl-propionyl)-2,2-dimethylpropionamide [ No CAS ]
  • 31
  • [ 1192852-05-3 ]
  • [ 309947-86-2 ]
  • [ 1192853-09-0 ]
  • 32
  • [ 1192852-84-8 ]
  • [ 309947-86-2 ]
  • [ 1192852-32-6 ]
  • 33
  • [ 1192852-86-0 ]
  • [ 309947-86-2 ]
  • [ 1192852-34-8 ]
  • 34
  • [ 1192852-88-2 ]
  • [ 309947-86-2 ]
  • [ 1192852-36-0 ]
  • 35
  • [ 1192852-90-6 ]
  • [ 309947-86-2 ]
  • [ 1192852-39-3 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 309947-86-2 ]

Amides

Chemical Structure| 354112-08-6

A167459 [354112-08-6]

N,N-DiBoc-4-amino-6-chloropyrimidine

Similarity: 0.65

Chemical Structure| 634468-96-5

A225813 [634468-96-5]

tert-Butyl 4-(pyrimidin-5-yl)piperazine-1-carboxylate

Similarity: 0.63

Chemical Structure| 4005-49-6

A170278 [4005-49-6]

N-(7H-Purin-6-yl)benzamide

Similarity: 0.62

Chemical Structure| 221050-89-1

A302723 [221050-89-1]

tert-Butyl 4-(pyrimidin-4-yl)piperazine-1-carboxylate

Similarity: 0.61

Chemical Structure| 1250996-70-3

A100090 [1250996-70-3]

tert-Butyl 2-(hydroxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate

Similarity: 0.60

Amines

Chemical Structure| 938-55-6

A103153 [938-55-6]

N,N-Dimethyl-7H-purin-6-amine

Similarity: 0.70

Chemical Structure| 31383-66-1

A249379 [31383-66-1]

2-((6-Amino-1H-purin-1-yl)methoxy)ethanol

Similarity: 0.69

Chemical Structure| 443-72-1

A345563 [443-72-1]

N-Methyl-7H-purin-6-amine

Similarity: 0.67

Chemical Structure| 354112-08-6

A167459 [354112-08-6]

N,N-DiBoc-4-amino-6-chloropyrimidine

Similarity: 0.65

Chemical Structure| 25477-96-7

A174863 [25477-96-7]

Ethyl adenine-9-acetate

Similarity: 0.62

Related Parent Nucleus of
[ 309947-86-2 ]

Purines

Chemical Structure| 938-55-6

A103153 [938-55-6]

N,N-Dimethyl-7H-purin-6-amine

Similarity: 0.70

Chemical Structure| 31383-66-1

A249379 [31383-66-1]

2-((6-Amino-1H-purin-1-yl)methoxy)ethanol

Similarity: 0.69

Chemical Structure| 443-72-1

A345563 [443-72-1]

N-Methyl-7H-purin-6-amine

Similarity: 0.67

Chemical Structure| 25477-96-7

A174863 [25477-96-7]

Ethyl adenine-9-acetate

Similarity: 0.62

Chemical Structure| 4005-49-6

A170278 [4005-49-6]

N-(7H-Purin-6-yl)benzamide

Similarity: 0.62